Online inquiry

IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12879MR)

This product GTTS-WQ12879MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12879MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11878MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ12652MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ14730MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ11155MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ5965MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ5855MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ15600MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ12832MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW